Laboratory for Integrative Neuroscience, National Institute on Alcohol Abuse and Alcoholism, National Institutes of Health, Rockville, MD 20852, USA.
Parkinsonism Relat Disord. 2012 Jan;18 Suppl 1(Suppl 1):S132-4. doi: 10.1016/S1353-8020(11)70041-4.
Endocannabinoids (eCBs) are lipid metabolites found throughout the nervous system that modulate synaptic plasticity mainly via actions on the cannabinoid 1 (CB1) receptor. Within the striatum, eCBs and CB1Rs initiate both short- and long-lasting synaptic depression at intrinsic GABAergic synapses and glutamatergic synapses made by cortical afferents. Recent studies have explored the mechanisms underlying eCB-mediated synaptic depression, and the role of this plasticity in striatal function. Dopamine (DA) and its receptors promote eCB-mediated depression of glutamatergic synapses, and dopamine depletion in animal models alters corticostriatal synapses in ways that may contribute to Parkinson's disease (PD). A growing body of literature indicates that alterations in eCB signaling occur in PD patients, suggesting possible therapeutic approaches targeting this neuromodulatory system.
内源性大麻素(eCBs)是在神经系统中发现的脂质代谢物,主要通过作用于大麻素 1(CB1)受体来调节突触可塑性。在纹状体中,eCBs 和 CB1Rs 在内在 GABA 能突触和皮质传入的谷氨酸能突触上引发短时间和长时间的突触抑制。最近的研究探讨了 eCB 介导的突触抑制的机制,以及这种可塑性在纹状体功能中的作用。多巴胺(DA)及其受体促进谷氨酸能突触的 eCB 介导的抑制,而动物模型中的多巴胺耗竭以可能导致帕金森病(PD)的方式改变皮质纹状体突触。越来越多的文献表明,PD 患者的 eCB 信号发生改变,这表明可能针对这种神经调制系统的治疗方法。